Figure 2.

Adoptive T cell therapy. Peripheral blood lymphocytes (PBLs) or tumor infiltrating lymphocytes (TILs) are collected and antigen-specific or non-specific expansions can be performed depending on the source of T cells and their tumor antigen reactivity. Addition of antigen specific receptors and additions/deletions of stimulatory/inhibitory receptors can be achieved with genetic engineering prior to the expansion of T cells. Once desired quantity of these cells is reached through expansion, they are reinfused into the patient.